Fusion Antibodies Management
Management criteria checks 2/4
Fusion Antibodies' CEO is Adrian Kinkaid, appointed in Aug 2022, has a tenure of 2.33 years. total yearly compensation is £179.00K, comprised of 94.4% salary and 5.6% bonuses, including company stock and options. directly owns 0.78% of the company’s shares, worth £50.25K. The average tenure of the management team and the board of directors is 1.8 years and 2.9 years respectively.
Key information
Adrian Kinkaid
Chief executive officer
UK£179.0k
Total compensation
| CEO salary percentage | 94.4% |
| CEO tenure | 2.3yrs |
| CEO ownership | 0.8% |
| Management average tenure | 1.8yrs |
| Board average tenure | 2.9yrs |
Recent management updates
Recent updates
Here's Why We're Not At All Concerned With Fusion Antibodies' (LON:FAB) Cash Burn Situation
Aug 31
Here's Why We're Not Too Worried About Fusion Antibodies' (LON:FAB) Cash Burn Situation
Jan 25We Think Fusion Antibodies (LON:FAB) Can Easily Afford To Drive Business Growth
May 09Investors Who Bought Fusion Antibodies (LON:FAB) Shares A Year Ago Are Now Up 146%
Mar 17Companies Like Fusion Antibodies (LON:FAB) Can Afford To Invest In Growth
Jan 04CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -UK£2m |
| Jun 30 2024 | n/a | n/a | -UK£2m |
| Mar 31 2024 | UK£179k | UK£169k | -UK£2m |
| Dec 31 2023 | n/a | n/a | -UK£3m |
| Sep 30 2023 | n/a | n/a | -UK£3m |
| Jun 30 2023 | n/a | n/a | -UK£3m |
| Mar 31 2023 | UK£183k | UK£111k | -UK£3m |
Compensation vs Market: Adrian's total compensation ($USD225.08K) is below average for companies of similar size in the UK market ($USD348.94K).
Compensation vs Earnings: Adrian's compensation has been consistent with company performance over the past year.
CEO
Adrian Kinkaid (57 yo)
2.3yrs
Tenure
UK£179,000
Compensation
Dr. Adrian Robert Kinkaid, Ph D., serves as Chief Executive Officer of Fusion Antibodies plc since August 15, 2022. and serves as its Director since August 25, 2022.He serves as Chief Executive Officer of...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | UK£179.00k | 0.78% £ 50.2k | |
| Chief Scientific Officer & Director | 3.9yrs | UK£122.00k | 1.04% £ 67.0k | |
| Founder | no data | no data | no data | |
| Company Secretary | 1.3yrs | no data | no data | |
| Operations Manager | 1.2yrs | no data | no data |
1.8yrs
Average Tenure
50yo
Average Age
Experienced Management: FAB's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | UK£179.00k | 0.78% £ 50.2k | |
| Chief Scientific Officer & Director | 13.3yrs | UK£122.00k | 1.04% £ 67.0k | |
| Company Secretary | 1.3yrs | no data | no data | |
| Non-Executive Chairman | 13.3yrs | UK£18.00k | 0.85% £ 54.9k | |
| Non-Executive Director | 17.9yrs | no data | 1.21% £ 77.9k | |
| Member of Scientific Advisory Panel & Independent Non-Executive Director | 2.9yrs | UK£21.00k | 0.16% £ 10.5k | |
| Member of Scientific Advisory Panel | 2.9yrs | no data | no data |
2.9yrs
Average Tenure
55.5yo
Average Age
Experienced Board: FAB's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 13:10 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fusion Antibodies plc is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robin Davison | Allenby Capital Limited |